- CODEN : IAJPBB
- issn 2349-7750
TITLE:
EFFECTS OF LACTOBACILLUS CASEI PROBIOTIC ON MILD TO MODERATE ULCERATIVE COLITIS: A PLACEBO CONTROLLED STUDY
AUTHORS:
Dr. Muhammad Bilal, Dr.Abdul Rauf, Dr.Arslan Ahmad Bakhsh
ABSTRACT:
Background: The effects of probiotics on ulcerative colitis has still remained a controversy. The aim of this study was to assess the effects of Lactobacillus casei strain ATCC PTA‑3945 in treating ulcerative colitis. Materials and Methods: Thirty-four patients with mild to moderately active ulcerative colitis randomly received a probiotic preparation of L. casei strain ATCC PTA‑3945 (n = 17) or its placebo (n = 17) plus conventional medical therapy for their active disease. After a maximum of 2 months, remitted patients were again randomised to receive L. casei strain ATCC PTA‑3945 or placebo, and also maintained on mesalazine or sulfasalazine tablets for a maximum of 6 months. Results: There was no statistical difference between probiotic and placebo groups (82% vs. 76% at intention to treat analysis [P = 1.00], and 100% vs. 81.2% at per‑protocol analysis [P = 0.23], respectively). 25 days and 32 days respectively was the clinical remission time period in probiotic and placebo groups, respectively (P = 0.11). Relapse rates also did not significantly differ between probiotic and placebo groups (14.3% vs. 26.7% at ITT analysis [P = 0.65] and 16.7% vs. 33.3% [P = 0.64], respectively). 96 days and 74 days was the mean time to relapse in the probiotic and the placebo group, respectively (P = 0.51). Conclusion: The results of this preliminary study showed no significant effect by using L. casei strain ATCC PTA‑3945 probiotic in the treatment of ulcerative colitis patients. Key words: Lactobacillus casei, probiotic, ulcerative colitis
FULL TEXT
<Approved Journal
NLM ID:101711216 [Serial]
Included in EuroPub database
ICV 2015 - 61.16
Indexed In
S.J Impact Factor:7.157
cosmos Impact Factor:4.153
ICMJE Recommendations
IP Indexing Impact Factor: 2.76
Cover Page
